Who truly benefits from gilteritinib combinations in FLT3-mutated relapsed-refractory(R/R) AML: a Canadian single center analysis.

ABSTRACT:

SUBMITTER: Rajendra A 

PROVIDER: S-EPMC12378385 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature